CoChat

Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts

Open access

The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.

Abstract

Acute myeloid leukemia (AML) is the most common type of acute leukemia, affecting older individuals at a median age of 67 years. Resistance to intensive induction chemotherapy is the major cause of death in elderly AML; hence, novel treatment strategies are warranted. CD33-directed antibody-drug conjugates (gemtuzumab ozogamicin) have been shown to improve overall survival, validating CD33 as a target for antibody-based therapy of AML. Here, we report the in vitro efficacy of BI 836858, a fully human, Fc-engineered, anti-CD33 antibody using AML cell lines and primary AML blasts as targets. BI 836858-opsonized AML cells significantly induced both autologous and allogeneic natural killer (NK)-cell degranulation and NK-cell-mediated antibody-dependent cellular cytotoxicity (ADCC). In vitro treatment of AML blasts with decitabine (DAC) or 5-azacytidine, 2 hypomethylating agents that show efficacy in older patients, did not compromise BI 836858-induced NK-cell-mediated ADCC. Evaluation of BI 836858-mediated ADCC in serial marrow AML aspirates in patients who received a 10-day course of DAC (pre-DAC, days 4, 11, and 28 post-DAC) revealed significantly higher ADCC in samples at day 28 post-DAC when compared with pre-DAC treatment. Analysis of ligands to activating receptors (NKG2D) showed significantly increased NKG2D ligand [NKG2DL] expression in day 28 post-DAC samples compared with pre-DAC samples; when NKG2DL receptor was blocked using antibodies, BI 836858-mediated ADCC was significantly decreased, suggesting that DAC enhances AML blast susceptibility to BI 836858 by upregulating NKG2DL. These data provide a rationale for combination therapy of Fc-engineered antibodies such as BI 836858 with azanucleosides in elderly patients with AML.

Overview

Integrity signals

Registry

Crossref · 10.1182/blood-2015-11-680546

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 38 references

Cited by

See all 93

Metadata

Authors
Vasu, S., He, S., Cheney, C., Gopalakrishnan, B., Mani, R., Lozanski, G., Mo, X., Groh, V., Whitman, S. P., Konopitzky, R., Kössl, C., Bucci, D., Lucas, D. M., Yu, J., Caligiuri, M. A., Blum, W., Adam, P. J., Borges, E., Rueter, B., Heider, K.-H., Marcucci, G., & Muthusamy, N.
Affiliations
  • The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
  • The Ohio State University (US)
  • University of Washington (US)
  • Boehringer Ingelheim (Austria) (AT)
  • Boehringer Ingelheim (Germany) (DE)
  • City Of Hope National Medical Center (US)
Corresponding author
  • Vasu, Sumithira
  • He, Shun
  • Heider, Karl-Heinz
  • Marcucci, Guido
  • Muthusamy, Natarajan
Venue
Blood
Published
2016-06-09
Volume
127
Issue
23
Pages
2879-2889
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2417767096
Cited by
93
References
39
Citations by year
2026: 4 · 2025: 6 · 2024: 4 · 2023: 6 · 2022: 11 · 2021: 12 · 2020: 13 · 2019: 10 · 2018: 12 · 2017: 12 · 2016: 3
FWCI
11.74
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Blood (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (P01CA095426, R37CA068458, R01CA068458, R01CA135332, P30CA016058)
Topics
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords
acute myeloid leukemia, decitabine, anti-CD33 monoclonal antibody, antibody-dependent cellular cytotoxicity, natural killer cells, NKG2D ligands, NKG2D, azanucleosides, azacitidine, hypomethylating agents, combination therapy, elderly patients, Fc-engineered antibody, CD33
MeSH terms
Decitabine, Antibodies, Monoclonal, Antibody-Dependent Cell Cytotoxicity, Antineoplastic Combined Chemotherapy Protocols, Azacitidine, Cells, Cultured, Combined Modality Therapy, Cytotoxicity, Immunologic, Drug Synergism, Humans, Immunoglobulin Fc Fragments, Killer Cells, Natural, Recombinant Proteins, Leukemia, Myeloid, Acute, HL-60 Cells, Antibodies, Monoclonal, Humanized, Sialic Acid Binding Ig-like Lectin 3

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts. https://app.cochat.ai/papers/10.1182/blood-2015-11-680546
The paper
Vasu, S., He, S., Cheney, C., Gopalakrishnan, B., Mani, R., Lozanski, G., Mo, X., Groh, V., Whitman, S. P., Konopitzky, R., Kössl, C., Bucci, D., Lucas, D. M., Yu, J., Caligiuri, M. A., Blum, W., Adam, P. J., Borges, E., Rueter, B., . . . Muthusamy, N. (2016). Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts. Blood. https://doi.org/10.1182/blood-2015-11-680546

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.